Product Dossier
AIROMIR
Product Dossier for AIROMIR (salbutamol (as sulfate), iNova Pharmaceuticals). ARTG record, PBS listing, PBAC outcomes — compiled by arcimedes.
- Sponsor: iNova Pharmaceuticals
- Active ingredient: salbutamol (as sulfate)
- Therapeutic area: Respiratory
- Same area: NUCALA
- Same area: VENTOLIN
What it is
AIROMIR is a salbutamol (as sulfate) inhalation aerosol. It is available as a pressurised inhalation in a breath actuated device delivering 100 micrograms per dose.
Approved indications
The provided sources do not contain information about the approved indications for AIROMIR inhalation aerosol. The product information available describes a different salbutamol formulation (intravenous injection for obstetric use) and does not specify respiratory indications for the inhaled product.
Dosing overview
The provided sources do not contain dosing information for AIROMIR inhalation aerosol.
Key safety warnings
The provided sources do not contain safety information specific to AIROMIR inhalation aerosol.
Contraindications
The provided sources do not contain contraindication information for AIROMIR inhalation aerosol.
PBS listing
AIROMIR pressurised inhalation in breath actuated device 100 micrograms per dose (CFC-free formulation) is listed on the PBS with restriction. The ex-manufacturer price is A$13.01. The listing comprises one PBS item.
Regulatory history
AIROMIR INHALER (100 microgram per metered dose inhalation aerosol) was first listed on the ARTG on 19 August 1998. AIROMIR AUTOHALER (100 microgram per dose metered dose aerosol) was first listed on the ARTG on 6 January 1999.